| 标题 |
 Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab 相关领域
阿替唑单抗
医学
肺癌
肿瘤科
内科学
免疫疗法
生物标志物
液体活检
癌症
彭布罗利珠单抗
生物化学
化学
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are broadly efficacious, improved outcomes have been observed in patients with high PD-L1 expression or high tumor mutational burden (TMB). PD-L1 testing is required for checkpoint inhibitor monotherapy in front-line non-small-cell lung cancer (NSCLC). However, obtaining adequate tumor tissue for molecular testing in patients with advanced disease can be challenging. Thus, an unmet medical need exists for diagnostic approaches that do not require tissue to identify patients who may benefit from immunotherapy. Here, we describe a novel, technically robust, blood-based assay to measure TMB in plasma (bTMB) that is distinct from tissue-based approaches. |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时，文件已从服务器自动删除，无法下载。 |
|
温馨提示：该文献已被科研通 学术中心 收录，前往查看
科研通『学术中心』是文献索引库，收集文献的基本信息（如标题、摘要、期刊、作者、被引量等），不提供下载功能。如需下载文献全文，请通过文献求助获取。
|
PDF的下载单位、IP信息已删除
(2025-6-4)
Copyright
cdercder
GingerF
DKJ
Jason
5_羟色胺
无极微光
番茄酱酱酱
落寞灵萱
lizishu
OK
羞涩的如豹
Yini
MchemG
昏睡的蟠桃
初景
gggggone
mmyhn
arbitmomo
ZOE
皖公网安备34019202002308
